

Artificial Intelligence in Obstetric Anesthesia for Hypertensive Disorders of Pregnancy: A Narrative Review

Dariush Abtahi^{1*}, Ebtehaj Heshmatkhah²

¹Department of Anesthesiology, School of Medicine, Clinical Research and Development Unit of Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

²Department of Obstetrics and Gynecology, Valiasr Private Hospital, Qom, Iran.

ARTICLE INFO

Article history:

Received 24 October 2025

Revised 14 November 2025

Accepted 28 November 2025

Keywords:

Hypertension;

Pregnancy-induced;

Preeclampsia;

Artificial intelligence;

Anesthesia;

Obstetric

ABSTRACT

Background: Hypertensive disorders of pregnancy, including preeclampsia and eclampsia, represent a significant global maternal health challenge, affecting 2-8% of pregnancies worldwide and contributing to 11-14% of maternal deaths. The complex, multisystemic nature of these conditions, coupled with their unpredictable clinical trajectories, presents substantial challenges for anesthetic management. This narrative review examines the emerging integration of artificial intelligence (AI) technologies in obstetric anesthesia care for hypertensive disorders, exploring current applications, technological foundations, implementation challenges, and future directions. We synthesize evidence demonstrating AI's potential in continuous monitoring, predictive analytics, personalized care delivery, and clinical decision support. While significant barriers to implementation exist-including technological, regulatory, and ethical considerations-the integration of AI into obstetric anesthesia represents a paradigm shift toward precision, predictive, and personalized maternal care. This narrative review synthesizes current evidence to argue that the primary value of AI in this context is not the replacement of clinical judgment, but its augmentation through the synthesis of high-dimensional, time-series data, thereby enhancing anesthesiologist situation awareness and enabling proactive, rather than reactive, management.

Introduction

Hypertensive disorders of pregnancy constitute a major global public health concern, with profound implications for maternal and neonatal morbidity and mortality. Current epidemiological data indicate that preeclampsia and eclampsia affect between 2% and 8% of pregnancies globally, translating to approximately 36 million cases annually [1-2]. The challenge posed by these diseases has continued to create an unequal burden, reflecting sharp disparities between resource-rich and resource-poor countries. Developed healthcare sectors have adequate surveillance and access to evidence-based therapy, but resource-poor areas are faced with significant hurdles,

such as late diagnosis, poor availability of magnesium sulfate, and lack of intensive care services. This contributes to these conditions being among the causes of uterine rupture and 11-14% of all maternal deaths [3-5].

The management strategy hinges on achieving adequate maternal hemodynamic stability while optimizing fetal perfusion and timing delivery. There ought to be an informed selection of anesthetic approaches based on the need for delivery with consideration of the coagulation status of the mother based on the platelet level. Cases of inaccuracies or failures in speedy screening as well as the handling of such situations may easily lead to devastating consequences for the mother in the form of hemorrhage or eclampsia seizure.

The authors declare no conflicts of interest.

*Corresponding author.

E-mail address: drdariushabtahi@yahoo.com

DOI:

The pathophysiologic basis of preeclampsia is rooted in systemic endothelial dysfunction and extends beyond blood pressure abnormalities to abnormalities in the coagulation mechanism, fluid equilibrium, uteroplacental blood flow, and multi-organ derangement [6-7]. The salient points include:

1. **Endothelial Glycocalyx Damage:** Vascular endothelial glycocalyx layer injury, resulting in capillary leak, general edema, and subsequent significant changes intravascular volume.

2. **Renin-Angiotensin System Dysfunction:** Abnormal placental production of anti-angiogenic factors (e.g., sFlt-1) antagonizes endothelial repair mechanisms (VEGF).

3. **Hypercoagulability:** While thrombocytopenia is present, a prothrombotic state is generally found, as evidenced by the increased levels of thrombin-antithrombin complexes. The extensive pathophysiologic changes demand anesthetic care focused on hemodynamic stabilization and the treatment of coagulopathy, among other conditions like pulmonary edema, cerebral edema, and renal dysfunction—each affecting pharmacokinetics differently

[8-9]. As the kinetic changes dynamically develop often within minutes during labor or during surgical procedures, they cannot be effectively detected by intermittent monitoring by the anesthesiologist.

The review aims to (1) assess the current status of artificial intelligence (AI) application usage in the management of hypertensive disorders during pregnancy, (2) critically analyze the existing technology support required to fully integrate AI into routine healthcare delivery, (3) critically appraise the challenges involved in implementing AI within technological, governance, and policy frameworks, (4) examine the future forecast regarding AI application usage in obstetric anesthetic practice, and (5) critically assess the future benefit and intensity unfolded by AI application in improving hypertensive disorders during pregnancy from the perspective of resource-challenged settings. In our synthesis approach to reviewing the current literature and existing technological developments, we attempt to identify the types of situations where value can still be added to the physician's expertise and judgment by the application of AI in obstetric anesthesia practiced on hypertensive disorders during pregnancy patients.

The Anesthetic Challenge: Managing Clinical Complexity in Real-Time

The core problem in the management of hypertensive pregnancy complications is the rapid transitions between

the states, requiring instantaneous changes in management.

• Hemodynamic Complexity and Clinical Unpredictability

The anesthetic concerns of parturients with hypertensive disorders have very complex dimensions. The hemodynamic involvement in preeclampsia includes a generalized vasoconstriction with intravascular volume depletion, depending upon the severity and duration of the disease [8, 9].

- **Vasopressor Response:** There is increased reactivity of the vasculature to exogenous vasopressors, such as phenylephrine, and the risk for hypertensive pulses with inexact dosing.

- **Fluid Management Paradox:** While excessive fluid resuscitation can induce pulmonary edema because of increased permeability and decreased oncotic pressure, the downside of fluid restriction could be the possible hypoperfusion of organs after regional anesthesia.

Moreover, under extreme conditions, anesthesiologists often make use of invasive monitoring methods such as Swan-Ganz catheters; however, AI has the potential for non-invasive extraction of similar information from waveforms.

This clinical dilemma generates conflicting data streams- low intravascular volume markers (e.g., pulse pressure variation) alongside signs of high extravascular lung water. An AI model could be trained to quantify the risk of pulmonary edema based on continuous analysis of respiratory compliance, subtle changes in oxygenation, and hemodynamic indices, providing a dynamic, personalized fluid responsiveness prediction that is superior to static measures.

Coagulopathy and Neuraxial Anesthesia Risk

Neuraxial techniques (epidural/spinal) are preferred for labor analgesia and Cesarean section due to lower risks of general anesthetic complications, but they are absolutely contraindicated if coagulation is severely impaired.

Thrombocytopenia and platelet dysfunction constitute major concerns during neuraxial anesthesia. HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) exemplifies severe disease with microangiopathy and hepatic injury [10-11].

The risk of neuraxial anesthesia is not fixed but depends on the risk of local bleeding. In the absence of general standards regarding the platelet count necessary for the safe performance of neuraxial anesthesia, it is necessary that an individualized risk-benefit calculation be undertaken, based on the trends in platelet count, coagulation studies (prothrombin time/international normalized ratio [PT/INR], activated partial thromboplastin time [aPTT]), as well as the degree of

clinical urgency [12]. The algorithms of artificial intelligence may integrate the changing values of the aforementioned variables with clinical findings (bruises, sites of active bleeding) in order to provide an individualized risk estimate regarding neuraxial procedures..

Neurological Manifestations

Eclampsia, defined by new-onset seizures, presents a neurological emergency requiring immediate airway, seizure control (often with magnesium sulfate), and blood pressure stabilization. Manifestations extend beyond convulsions to posterior reversible encephalopathy syndrome (PRES), cerebral hemorrhage, and cortical blindness [13-14]. Cerebral autoregulation is compromised in severe preeclampsia. Neuroimaging investigations document cerebral infarction, edema, hypoperfusion, and vasospasm in preeclampsia and eclampsia [15].

Anesthetic agents impact intracranial pressure (ICP) and cerebral perfusion pressure (CPP). The care of a patient post-eclamptic seizure involves a trade-off between antihypertensive drugs that decrease cerebral perfusion pressure (CPP) and drugs used for intracranial pressure management. Such a process requires a highly precise dosage adjustment, which is most appropriate for a feed-back-controlled system operating under artificial intelligence inputs.

Artificial Intelligence: Filling the Gaps in Human Capabilities

AI technology, especially machine learning (ML) and deep learning (DL), has strong capabilities in recognizing patterns in continuous high dimensional data, areas where human intelligence has natural limitations.

Continuous Multiparametric Monitoring

Modern operating theaters and delivery rooms produce immense amounts of data through patient monitoring. This is because AI makes it possible to monitor patients continuously over complex datasets by simulating, at the same time, changes in blood pressure variability, heart rate, oxygen saturation, urine output, and fetal heart rate, thereby identifying subtleties known as potential correlations, which might not always be detected by human observation [16]. For example, a subtle decrease in pulse pressure and an increase in end-tidal carbon dioxide levels could show impending heart failure well before other alert levels have been reached.

Predictive Analytics and Early Warning Systems

Machine learning prediction allows for the first time in history the shift of focus in management from reaction

to prevention. Based on massive data inputs, such as thousands of deliveries complicated by severe preeclampsia, artificial intelligence systems detect minute patterns that precede complications hours in advance [17-18].

For example, a seizure prediction model based on continuous data from an arterial line can provide information regarding the probability of a severe hypertensive surge during induction of general anesthesia in the coming 15 minutes. This method has a reported sensitivity of over 85% based on beat-to-beat variability. This offers an anesthesiologist a possible chance to prevent an occurrence of a hypertensive surge or a seizure using vasodilators or magnesium sulfate.

Personalized Medicine and Personalized Anesthesia

recognize the fact that one-size-fits-all dosage regimens often fail in complex physiological situations such as severe preeclampsia. This is because of changes in the volume of distribution, protein-binding changes due to hypoalbuminemia, and varying amounts of renal and hepatic dysfunction. AI systems incorporate genetic polymorphisms, obstetric history, current vital signs, and the latest laboratory parameters to generate patient-specific algorithms [19-20].

A practical example would be how a loading dose of magnesium sulfate, an anticonvulsant drug that has the possibility of toxicity, requires accurate estimation of creatinine clearance and volume of distribution. By using an AI system, it is possible to modify the calculation depending on the values derived in real-time for creatinine levels, urinary output, and the estimated clearance. This is personalized and adds an improved level of individualization to the pharmacological management.

Data Integration and Synthesis

One big challenge to the decision-making process is the manual integration of the different sources of information. Artificial intelligence brings together information from the electronic medical records system (EHR), the continuous patient monitoring system, the lab information system, imaging information (such as brain MRI findings related to posterior reversible encephalopathy syndrome or PRES), and even wearable technology into integrated models informed by the relevant context specifically for the information accessed or reviewed [21-22]. This framework provides the decision support system with the necessary relationships between blood pressure values and other variables that have been identified. This synthesis enables the conversion of raw data to clinical knowledge.

Technological Infrastructure: Enabling AI in Clinical Practice

The feasibility of sophisticated AI deployment in acute care settings like obstetrics is predicated on recent advancements in hardware, data handling, and connectivity.

Computational Advances

The transition from theoretical models to deployable, real-time clinical decision support systems relies heavily on computational power. Recent technological progress-including Graphics Processing Units (GPUs) and specialized AI accelerators (e.g., TPUs)- enables the real-time execution of intensive deep learning algorithms, such as those required for complex waveform segmentation and interpretation [23-24]. Cloud and edge computing architectures allow cloud deployment for retrospective model training on massive datasets and edge computing (processing directly on local monitors or servers) for ultra-low-latency, real-time inference in the operating room [24].

Advanced Sensor Technology

AI is only as good as its input data. Modern sensors capture high-resolution physiologic data for continuous evaluation, moving beyond simple threshold alarms. Non-invasive measures such as beat-to-beat blood pressure derived from plethysmography, cardiac output estimation using advanced pulse contour analysis, and continuous oxygenation integrated with laboratory data (e.g., continuous hematocrit trends) provide the rich data streams necessary for deep learning models [25].

Natural Language Processing (NLP)

Much critical clinical information regarding hypertensive disorders resides in unstructured text: nursing notes detailing patient complaints ("I feel dizzy," "I saw spots"), physician progress notes describing seizure activity, or anesthesia handover summaries. Natural Language Processing (NLP): NLP is used for identifying important clinical information in unstructured clinical documentation, standardizing and quantifying unstructured clinical data in order to integrate it into predictive models [26].

AI Explainability and Clinical Acceptance

Doctors have traditionally been skeptical of "black box" algorithms, especially with regard to patient outcomes. XAI is working to alleviate this problem by promoting trust through open demonstrations of reasoning. Techniques like SHAP (SHapley Additive exPlanations) values and attention mechanisms help to point out which input features, such as platelet count or mean arterial pressure derivatives, impact most on those patients classified as high-risk [27]. This allows the anesthesiologist to cross-verify the machine's reasoning

against established physiology. Furthermore, healthcare interoperability standards like FHIR (Fast Healthcare Interoperability Resources) facilitate the secure exchange of structured data necessary for system integration and the development of federated learning approaches across multiple institutions [28].

Ensure that you return to the 'Els-body-text' style, the style that you will mainly be using for large blocks of text, when you have completed your bulleted list.

Implementation Challenges: From Research to Practice

Moving AI from pilot studies into standard clinical workflow introduces multifaceted non-technical hurdles.

Sociotechnical Considerations

Effective clinical integration extends beyond technology to encompass workflow design and ethical oversight. Introducing an AI alert system requires understanding how it impacts existing human-to-human communication (e.g., coordination between anesthesiologists and obstetricians) and modifying standard operating procedures to incorporate the AI's findings without causing alert fatigue [29-30].

User Interface Design

During the acute care of eclampsia, it is necessary to keep cognitive overload low. The design of the user interface needs to prioritize simplicity, speed, and actionable guidance. A dashboard with too many metrics, no matter how visually alluring, can add to cognitive overload, culminating in the ignoring of important notifications [31]. It needs to be made clear that some messages are just from the AI.

Clinical trust and validation

Clinical acceptance needs to be ensured through reliability, reflected by high positive predictive value and accuracy. Further, the degree of uncertainty needs to be clearly expressed. An AI model reporting a 50% risk of eclampsia should trigger different clinical responses than one reporting a 95% risk. Maintaining physician oversight- ensuring the final decision remains with the human expert- is paramount while the system continuously monitors in the background [32].

Regulatory Framework

Current medical device regulations are often ill-suited for "continuously learning systems" (CLS) that update their algorithms based on new real-world data. The regulatory bodies such as the FDA must establish guidelines on the liability for mistakes made in the AI algorithms, as well as the necessary documentation for AI intervention to be followed [33-34].

Resource Constraints in Low- and Middle-Income Countries (LMICs)

Although there is great promise for artificial intelligence (AI) applications with regard to lowering disparities of healthcare around the globe, existing conditions concerning power availability and networking capabilities are often suboptimal for initial use of such technology within LMICs [29]. However, development of scalable forms of such AI with potential use on portable devices such as tablets or low-end personal computers might make elite risk adjustment available and relieve current deficits of highly specialized obstetric critical care personnel [35].

Future Directions: Enhancing the Practice of Obstetric Anesthesia Using Artificial Intelligence

It would include a staged process of adoption in moving from decision-support systems to semi-autonomous intervention using AI.

Near-Term Applications

Short-term deployment contemplates risk stratification and decision support in a fully real-time fashion with a primary focus on risk detection for those likely to progress to a severe disease state. Earlier systems are contemplated to interoperate with a primary focus on alerting concerning trends in blood pressure variability, detection of subtle clues indicative of impending pulmonary edema via nuanced changes in measurements of pulmonary compliance, and alerting to either sub-therapeutic magnesium concentrations in association with seizure likelihood while maintaining physician dominance throughout [35-36].

Advanced Autonomous Systems

Medium-term progress could also allow for closed-loop autonomous dosage adjustment. As an example, an AI system controlling an infusion device for a drug such as labetalol or nicardipine could automatically vary the dosage of the drug according to continuous waveforms of arterial blood pressure and a set of defined targets if it could continue to perform robust safety analysis to address dangers posed by critical system failures [37].

These systems could also use AI and robotic systems for improved accuracy in placing a vascular or neuraxial procedure, using real-time ultrasound fusion [37].

Population Health and Preventative Medicine

Potential long term: the optimization of risk in the population and the prevention of preeclampsia via population screening. Through the examination of early pregnancy information like the first-trimester ultrasound and blood pressure values obtained early in pregnancy, artificial intelligence systems could forecast populations

at risk to receive aspirin or increased monitoring during pregnancy [38-39]. This transition to preemptive public health management offers the greatest potential for reducing overall maternal morbidity [39-40].

Economic Considerations

Although initial implementation costs for hardware, integration, and validation are substantial, the long-term return on investment arises through the prevention of severe complications.

Lower rates of intracranial hemorrhage, reduced needs for admission to the intensive care unit, lower total hospital stays, and more efficient use of resources (e.g., preventing the need for transfer when possible and preventing overmonitoring) are all sources of explicit cost savings [41].

Discussion

Implications for Maternal Health

The AI-anesthesia interface for hypertensive disorders transcends mere technological enhancement; it fundamentally redefines the paradigm of maternal critical care. The inherent complexity, high stakes, and dependence on integrating vast amounts of multi-modal, time-sensitive data make preeclampsia and eclampsia ideal test cases for systems capable of managing high-dimensional data under acute temporal constraints [42-43]. The integration of artificial intelligence into obstetric anesthesia management in hypertensive disorders offers a paradigm shift in addressing one of the biggest clinical challenges.

Limitations

The current level of proof for deploying AI technology in preeclampsia management remains primarily theoretical, using retrospective model data or derived from pilot research efforts on a small scale showing viability. There exists a critical and long-overdue requirement for randomized and prospective large-scale clinical trials to compare and validate AI-assisted management to standard management for clinical efficacy and safety on a broader scale [43].

Beyond a concern for lack of generalizability for algorithms across geography and culture on a broader scale, a model developed and trained using data strictly from a North American tertiary hospital may perform sub-optimally on a clinic in rural Asia using differences in demographics and sensor calibration adjustments to illustrate limitations. In addition, there still remain challenging areas for ethical development related to privacy and obtaining consent for using data for development.

Critical Success Factors

The success of adoption comes with harmonious progress in technical developments, regulatory certainty, as well as social acceptance by the medical fraternity. It is crucial, however, that AI systems be developed along with the aim of enhancing, rather than substituting, the role of human expertise—the best safety nets, problem-solving tools, and analytical aids. The objectives of predictability need to be met while retaining the critical role of ultimate decision-making by the physician. The plans of implementation worldwide need emphasis on collaboration by sources whenever possible, often a crucial concept towards creating a realistic means of narrowing the maternal mortality gaps worldwide [40].

Conclusion

The incorporation of artificial intelligence in the management of obstetric anesthesia for hypertensive disorders represents a revolutionary opportunity in meeting this major clinical problem. AI enables sophisticated, continuous multiparametric monitoring, delivers advanced predictive analytics, and provides data-driven decision support precisely when the human cognitive bandwidth is most taxed. The technological infrastructure, driven by computational power and advanced sensing, has matured sufficiently to support tangible, safe clinical deployment in many contexts.

Priorities for the next decade must include rigorous, large-scale validation trials to establish clinical superiority or non-inferiority. Research must focus on the engineering of continuous algorithm updating mechanisms that allow models to safely adapt to evolving clinical practices. Further refinement of human–AI interaction interfaces, comprehensive economic assessments demonstrating value, the establishment of clear ethical and legal frameworks, and concerted efforts toward ensuring equitable global access are essential. This convergence of medicine and computation signals a future of truly predictive and personalized maternal care, grounded equally in technological precision and unwavering human compassion.

Acknowledgment

The authors wish to express their sincere appreciation to the staff and faculty of the Department of Anesthesiology for their invaluable support throughout this study. We also extend our gratitude to the Clinical Research and Development Unit of Imam Hossein Hospital for their valuable assistance. Finally, we are deeply grateful to all the patients for their participation, cooperation, and trust.

References

- [1] World Health Organization. Pre-eclampsia [Internet]. Geneva: WHO; [cited 2025 Jan 10]. Available from: <https://www.who.int/news-room/fact-sheets/detail/pre-eclampsia>
- [2] Sun S, Li W, Zhang X, Aziz AU, Zhang N. Trends in global and regional incidence and prevalence of hypertensive disorders in pregnancy (1990–2021): an age-period-cohort analysis. *Sci Rep*. 2025; 15(1):1513.
- [3] Melesse MF, Aynalem GL, Badi MB, Aynalem BY. Maternal outcomes of severe preeclampsia and eclampsia and associated factors among women admitted at referral hospitals of Amhara regional state, Ethiopia. *Front Glob Womens Health*. 2025; 6:1555778.
- [4] Wojtowicz A, Zembala-Szczerba M, Babczyk D, Kołodziejczyk-Pietruszka M, Lewaczyńska O, Huras H. Early- and late-onset preeclampsia according to new ISSHP criteria. *Int J Hypertens*. 2019; 2019:4108271.
- [5] Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states. *Hypertension*. 2008; 52(5):873-80.
- [6] Lamarca B. Endothelial dysfunction: an important mediator in the pathophysiology of hypertension during pre-eclampsia. *Minerva Ginecol*. 2012; 64(4):309-20.
- [7] Powe CE, Levine RJ, Karumanchi SA. Preeclampsia: a disease of the maternal endothelium. *Circulation*. 2011; 123(24):2856-69.
- [8] Gyselaers W. Hemodynamic pathways of gestational hypertension and preeclampsia. *Am J Obstet Gynecol*. 2022; 226(2 Suppl):S988-S1005.
- [9] Lees C, Ferrazzi E. Relevance of haemodynamics in treating pre-eclampsia. *Curr Hypertens Rep*. 2017; 19(9):76.
- [10] Khalid F, Mahendraker N, Tonismae T. HELLP syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
- [11] Padden MO. HELLP syndrome: recognition and perinatal management. *Am Fam Physician*. 1999; 60(3):829-36.
- [12] Estcourt LJ, Malouf R, Hopewell S, Doree C, Van Veen J. Platelet transfusions before lumbar punctures or epidural anaesthesia. *Cochrane Database Syst Rev*. 2018; 4(4):CD011980.
- [13] Ghadiali T, Nguyen MT, Lee RH, Sasso EB. Atypical eclampsia in a normotensive patient. *Int J Gynaecol Obstet*. 2024; 164(2):476-81.
- [14] MedLink Neurology. Seizures associated with eclampsia [Internet]. Available from: <https://www.medlink.com/articles/seizures-associated-with-eclampsia>
- [15] Bergman L, Hannsberger D, Schell S, Imberg H, Langenegger E, Moodley A, et al. Cerebral infarcts and edema in preeclampsia and eclampsia. *Am J*

- Obstet Gynecol. 2025; 232(6):550.e1-550.e14.
- [16] Kong AYH, Liu N, Tan HS, Sia AT, Sng BL. Artificial intelligence in obstetric anaesthesiology. *Int J Obstet Anesth*. 2025; 61:104288.
 - [17] Ranjbar A, Montazeri F, Ghamsari SR, Mehrnoush V, Roozbeh N, Darsareh F. ML models for predicting preeclampsia: systematic review. *BMC Pregnancy Childbirth*. 2024; 24(1):6.
 - [18] Layton AT. Artificial intelligence and machine learning in preeclampsia. *Arterioscler Thromb Vasc Biol*. 2025; 45(2):165-71.
 - [19] Li T, Xu M, Wang Y, Wang Y, Tang H, Duan H, et al. Prediction model of preeclampsia using ML. *Front Endocrinol (Lausanne)*. 2024; 15:1345573.
 - [20] Wu Y, Shen L, Zhao L, Lin X, Xu M, Tu Z, et al. Noninvasive prediction of preeclampsia using retinal features. *NPJ Digit Med*. 2025; 8(1):188.
 - [21] World Economic Forum. 7 ways AI is transforming healthcare [Internet]. Available from: <https://www.weforum.org/stories/2025/08/ai-transforming-global-health/>
 - [22] Oppong SO, Twum F, Hayfron-Acquah JB, Missah YM. Computer vision model for medicinal plant identification. *Comput Intell Neurosci*. 2022; 2022:1189509.
 - [23] Accenture. Transforming healthcare with AI [Internet]. Available from: <https://www.accenture.com/us-en/blogs/health/accenture-technology-trends-2025-healthcare>
 - [24] Health care technology trends 2025 [Internet]. YouTube. Available from: <https://www.youtube.com/watch?v=8OWdxCJcQV>
 - [25] SS&C Blue Prism. The future of AI in healthcare – 2025 [Internet]. Available from: <https://www.blueprism.com/resources/blog/the-future-of-ai-in-healthcare/>
 - [26] Canadian Agency for Drugs and Technologies in Health. 2025 watch list: artificial intelligence in health care [Internet]. Ottawa (ON): CADTH; 2025 Mar. Report No.: ER0015.
 - [27] Stanford HAI. The 2025 AI Index Report [Internet]. Available from: <https://hai.stanford.edu/ai-index/2025-ai-index-report>
 - [28] Cicek V, Bagci U. Position of AI in healthcare and future perspective. *Artif Intell Med*. 2025; 167:103193.
 - [29] Adedinsewo DA, Onietan D, Morales-Lara AC, Moideen Sheriff S, Afolabi BB, Kushimo OA, et al. Challenges in AI implementation in low-resource settings. *Front Cardiovasc Med*. 2025; 12:1516088.
 - [30] Tadepalli K, Das A, Meena T, Roy S. Bridging gaps in AI adoption for obstetric care. *Comput Methods Programs Biomed*. 2025; 263:108682.
 - [31] Medjedovic E, Stanojevic M, Jonuzovic-Prosic S, Ribic E, Begic Z, Cerovac A, et al. AI in maternal-fetal medicine. *Technol Health Care*. 2024; 32(3):1273-87.
 - [32] Korytnikova E. AI and women's health: innovations and challenges. *Adv Clin Med Res*. 2023; 4(3):1-6.
 - [33] Elbiss HM, Abu-Zidan FM. AI in gynecologic and obstetric emergencies. *Int J Emerg Med*. 2025; 18(1):20.
 - [34] Fischer A, Rietveld A, Teunissen P, Hoogendoorn M, Bakker P. Future of AI in obstetrics. *BMJ Open*. 2023; 13(10):e076017.
 - [35] Mapari SA, Shrivastava D, Dave A, Bedi GN, Gupta A, Sachani P, et al. Role of AI in maternal health. *Cureus*. 2024; 16(9):e69555.
 - [36] Owoche PO, Shisanya MS, Mayeku B, Namusonge LN. Role of AI in reducing maternal mortality. *PLoS One*. 2025; 20(5):e0323533.
 - [37] Victor A. AI in maternal and child health. *PLOS Digit Health*. 2025; 4(7):e0000938.
 - [38] Cedars-Sinai. Artificial intelligence can improve OB-GYN care [Internet]. Available from: <https://www.cedars-sinai.org/newsroom/womens-health-month-artificial-intelligence-can-improve-ob-gyn-care/>
 - [39] Vasudevan L, Kibria M, Kucirka L, Shieh K, Wei M, Masoumi S, Balasubramanian S, Victor A, Conklin J, Gurcan M, Stuebe A, Page D Machine Learning Models to Predict Risk of Maternal Morbidity and Mortality From Electronic Medical Record Data: Scoping Review. *J Med Internet Res* 2025;27:e68225.
 - [40] Figo. From innovation to impact: revolutionising maternal health through femtech [Internet]. Available from: <https://www.figo.org/events/figo-webinars/innovation-impact-revolutionising-maternal-health-through-femtech>
 - [41] Nogueira M, Aparício SL, Duarte I, Silvestre M. Artificial Intelligence's Role in Improving Adverse Pregnancy Outcomes: A Scoping Review and Consideration of Ethical Issues. *J Clin Med*. 2025; 14(11):3860.
 - [42] Özhüner Y, Özhüner E. AI in improving maternal and fetal health. *Mediterr Nurs Midwifery*. 2025.
 - [43] Gates Foundation. The scientist using AI to improve maternal health [Internet]. Available from: <https://www.gatesfoundation.org/ideas/articles/ai-maternal-health-pakistan>